Orforglipron Research for Obesity
An evidence-based overview of research examining Orforglipron in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Orforglipron has demonstrated significant weight loss efficacy in large Phase 3 trials. ATTAIN-1 showed 12.4% weight loss at 72 weeks with the 36mg dose compared to 2.1% with placebo in 3,127 adults with obesity. This represents the first oral non-peptide GLP-1 agonist to show comparable efficacy to injectable alternatives.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Orforglipron may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.